We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.47B
1-Year Est. Return 115.63%
This Fund
S&P 500
This Quarter Est. Return
+16.74%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$189M
AUM Growth
+$13.2M
Cap. Flow
+$2.79M
Cap. Flow %
1.48%
Top 10 Hldgs %
41.3%
Holding
80
New
19
Increased
18
Reduced
20
Closed
17

Top Buys

Rank Stock Value
1
MRSN
Mersana Therapeutics
MRSN
+$7.94M
2
INBX
Inhibrx, Inc. Common Stock
INBX
+$7.37M
3
LNTH icon
Lantheus
LNTH
+$6.99M
4
NTRA icon
Natera
NTRA
+$5.75M
5
CMPS
Compass Pathways
CMPS
+$5.64M

Top Sells

Rank Stock Value
1
ZYME icon
Zymeworks
ZYME
+$11.4M
2
AZN icon
AstraZeneca
AZN
+$7.06M
3
PRTA icon
Prothena Corp
PRTA
+$7.06M
4
SYRE icon
Spyre Therapeutics
SYRE
+$3.42M
5
LLY icon
Eli Lilly
LLY
+$3.41M

Sector Composition

Rank Sector Weight
1 Healthcare 94.21%
2 Real Estate 0.86%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HARP
51
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$722K 0.38%
4,247
+1,158
+37% +$167K
PCRX icon
52
Pacira BioSciences
PCRX
$1B
$613K 0.32%
10,200
-2,000
-16% -$116K
ENTA icon
53
Enanta Pharmaceuticals
ENTA
$396M
$526K 0.28%
11,500
– –
AZN icon
54
AstraZeneca
AZN
$249B
$504K 0.27%
4,602
-63,505
-93% -$7.06M
KYMR icon
55
Kymera Therapeutics
KYMR
$8.81B
$495K 0.26%
+15,305
New +$467K
FATE icon
56
Fate Therapeutics
FATE
$296M
$388K 0.21%
9,712
-23,288
-71% -$813K
CSTL icon
57
Castle Biosciences
CSTL
$964M
$323K 0.17%
6,269
-8,731
-58% -$388K
IRTC icon
58
iRhythm Holdings
IRTC
$4.25B
$283K 0.15%
+1,187
New +$210K
AFMD
59
DELISTED
Affimed
AFMD
$232K 0.12%
+6,849
New +$259K
CNST
60
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$218K 0.12%
10,742
-22,658
-68% -$553K
COGT icon
61
Cogent Biosciences
COGT
$7.22B
$112K 0.06%
+11,975
New +$125K
ABBV icon
62
AbbVie
ABBV
$432B
– –
-28,900
Closed -$2.84M
ARVN icon
63
Arvinas
ARVN
$570M
– –
-6,000
Closed -$201K
FOLD
64
DELISTED
Amicus Therapeutics
FOLD
– –
-127,300
Closed -$1.92M
HUM icon
65
Humana
HUM
$45.9B
– –
-6,600
Closed -$2.56M
INSP icon
66
Inspire Medical Systems
INSP
$1.72B
– –
-5,608
Closed -$488K
LLY icon
67
Eli Lilly
LLY
$1.05T
– –
-20,800
Closed -$3.41M
MASI
68
DELISTED
Masimo
MASI
– –
-3,400
Closed -$775K
PRTA icon
69
Prothena Corp
PRTA
$453M
– –
-674,603
Closed -$7.06M
RAPT
70
DELISTED
RAPT Therapeutics
RAPT
– –
-1,888
Closed -$438K
RLMD icon
71
Relmada Therapeutics
RLMD
$526M
– –
-6,900
Closed -$308K
SYRE icon
72
Spyre Therapeutics
SYRE
$9.16B
– –
-14,794
Closed -$3.42M
ZYME icon
73
PUT
Zymeworks
ZYME
$1.74B
– –
-327,900
Closed -$11.8M
NARI
74
DELISTED
Inari Medical, Inc. Common Stock
NARI
– –
-65,817
Closed -$3.19M
SILK
75
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
– –
-27,711
Closed -$1.16M
1 2
3
4

Similar funds

TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return
Q
QVR San Francisco, California $2.49B AUM 48.58% 1-Year Est. Return
SIM
Stratos Investment Management Beachwood, Ohio $2.49B AUM 17.24% 1-Year Est. Return
QT
Quantbot Technologies New York $2.44B AUM 17.13% 1-Year Est. Return

Soleus Capital Management's Q3 2020 Portfolio in Review

As of Q3 2020, Soleus Capital Management held 80 positions worth $189M, up 7.5% from $175M the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Soleus Capital Management's Q3 2020 filing shows 19 new, 18 increased, 20 reduced and 17 closed positions. Its largest new stake was Mersana Therapeutics: 15,722 shares worth $7.32M. The largest sale was Zymeworks, an estimated $11.4M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 89% a quarter earlier, followed by Real Estate.

  • Soleus Capital Management's largest Q3 2020 buy was Mersana Therapeutics: 15,722 shares worth $7.32M.
  • Soleus Capital Management added most to OraSure Technologies in Q3 2020, an estimated $5.49M increase.
  • Soleus Capital Management's biggest Q3 2020 reduction was Zymeworks, cutting an estimated $11.4M.
  • Soleus Capital Management fully exited Prothena Corp in Q3 2020, selling an estimated $7.06M.
  • Soleus Capital Management's ten largest holdings make up 41% of its $189M portfolio in Q3 2020.
  • Soleus Capital Management opened 19 new positions and closed 17 in Q3 2020.
  • Soleus Capital Management's portfolio value rose 7.5% quarter-over-quarter to $189M.

Based on Soleus Capital Management's 13F filing for Q3 2020, filed 13 Nov 2020.